NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES THAN THOSE REQUIRED BY SWEDISH LAW. SEE ALSO THE SECTION ”IMPORTANT INFORMATION” BELOW.
Ziccum AB (publ) (”Ziccum” or the ”Company”) today publishes an Information Memorandum regarding the Company’s forthcoming rights issue of units (“Units”) consisting of shares and warrants resolved by the Board of Directors on 22 January 2024 (the ”Rights Issue”). The information memorandum, which is written in English, is available on the Company’s website (www.ziccum.com) and on Aqurat’s website (www.aqurat.se).
Ziccum today publishes an information memorandum regarding the Company’s forthcoming Rights Issue. The information memorandum, which is written in the Company’s official language for information disclosure, English, is available on the Company’s website (www.ziccum.com) and on Aqurat’s website (www.aqurat.se).
Terms for the Rights Issue
- The Rights Issue comprises a maximum of 1,534,015 Units, where each Unit consists of one (1) new share and one (1) warrant of series TO5 (the ”Warrants”). In total, the Rights Issue thus comprises a maximum of 1,534,015 shares and 1,534,015 Warrants.
- Those who on the record date of 29 January 2024 are registered in the share register kept by Euroclear Sweden AB have pre-emption rights to subscribe for Units in the Rights Issue.
- One (1) existing share held on the record date entitles to one (1) unit right. Nine (9) unit rights entitle the holder to subscribe for one (1) Unit.
- The subscription price in the Rights Issue amounts to SEK 6.80 per Unit, corresponding to SEK 6.80 per share. The warrants are issued free of charge.
- The subscription period in the Rights Issue runs from and including 31 January 2024 to and including 14 February 2024.
- Trading in unit rights will take place on Nasdaq First North Growth Market from and including 31 January 2024 to and including 9 February 2024.
- Trading in BTU (paid subscribed unit) will take place on Nasdaq First North Growth Market from and including 31 January 2024 up until the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place around week nine (9), 2024.
- Ziccum expects to announce the outcome of the Rights Issue around 16 February 2024.
Preliminary timetable for the Rights Issue
- 31 January 2024 – 14 February 2024: Subscription period
- 31 January 2024 – 9 February 2024: Trading in unit rights
- 16 February 2024: Estimated date for publication of the outcome of the Rights Issue
Fredersen Advokatbyrå is legal advisor and Aqurat Fondkommission is acting as issuing agent in connection with the Rights Issue.
For more information, please contact
Ann Gidner, CEO
Mobile: +46 722140141
Fredrik Sjövall, Chairman of the Board
Mobile: +46 70 645 08 75
Carnegie Investment Bank AB (publ)
Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.
The publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer or an invitation to acquire or subscribe for any securities in Ziccum in any jurisdiction, neither from Ziccum nor from anyone else.
This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the ”Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared by the Company and published on the Company’s website in connection with the Rights Issue.
This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the ”Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in contravention of this guidance may constitute a breach of applicable securities laws.
In the United Kingdom, this document and other materials relating to the securities referred to herein are only being distributed and directed to, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, ”qualified investors” (as defined in section 86 (7) of the Financial Services and Markets Act 2000) who are (i) persons who have professional experience in matters relating to investments and who fall within the definition of ”investment professionals” in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ”Order”); or (ii) ”high net worth entities” as referred to in Article 49 (2)(a) to (d) of the Order (all such persons together being referred to as ”relevant persons”). An investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this announcement and should not act or rely on it.
As Ziccum has made the assessment that the Company conducts activities worthy of protection under The Foreign Direct Investment Screening Act (2023:560), certain investments in the Rights Issue may require review by the Swedish Inspectorate of Strategic Products. For more information, please visit the Swedish Inspectorate of Strategic Products’ website, www.isp.se, or contact the Company.
This press release contains forward-looking statements that reflect the Company’s intentions, beliefs or expectations regarding the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the fact that they contain expressions such as ”believes”, ”expects”, ”anticipates”, ”intends”, ”estimates”, ”will”, ”may”, ”assumes”, ”should”, ”could” and, in each case, negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialise or that they are accurate. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcomes may differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied by the forward-looking statements in this press release. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct and any reader of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein speak only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revision to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.